二甲双胍在每年接受MRI监测的Li-Fraumeni综合征成人中的癌症精准预防试验(MILI):一项随机对照试验方案
MILI是一项精准预防II期开放标签非盲随机对照试验,计划纳入224例≥16岁Li-Fraumeni综合征成人,1:1随机分为口服二甲双胍(每日最多2 mg)联合年度MRI监测组或单纯年度MRI监测组,干预最长5年;主要终点为随机化后5年内累积无癌生存,次要终点包括5年累积无肿瘤生存、总生存及新发癌症临床特征等。
要点
- MILI是首个在Li-Fraumeni综合征高危人群中开展的癌症预防试验。
- 224例≥16岁LFS成人按1:1随机接受口服二甲双胍(每日最多2 mg)联合年度MRI监测或单纯年度MRI监测,最长5年。
- 主要终点为随机化后5年(60个月)累积无癌生存,比较二甲双胍组与无二甲双胍对照组。
核心结论
- MILI是首个在Li-Fraumeni综合征高危人群中开展的预防试验,提供评估二甲双胍化学预防疗效并探索其抗癌机制及突变P53驱动肿瘤发生生物学过程的机会。
研究设计与样本
- MILI是一项精准预防II期开放标签非盲随机对照试验,计划纳入224例≥16岁Li-Fraumeni综合征成人,1:1随机分为口服二甲双胍(每日最多2 mg)联合年度MRI监测组或单纯年度MRI监测组,干预最长5年。
- 主要终点为比较干预组(二甲双胍)与对照组(无二甲双胍)随机化后5年(60个月)内累积无癌生存。
- 次要终点包括两组5年累积无肿瘤生存、5年总生存及新发癌症临床特征比较,以及二甲双胍安全性、毒性、可接受性、对生活质量的影响和基线生活方式危险因素对癌症发病率的影响。
- 探索性终点将评估二甲双胍作为癌症预防药物的作用机制、识别应答或癌变生物标志物,并通过评估WB-MRI的检出率和诊断准确性来评价其作为LFS患者癌症诊断工具的性能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Li-Fraumeni syndrome (LFS) is a rare autosomal dominant disease caused by inherited or de novo germline pathogenic variants in TP53. Individuals with LFS have a 70-100% lifetime risk of developing cancer. The current standard of care involves annual surveillance with whole-body and brain MRI (WB-MRI) and clinical review; however, there are no chemoprevention agents licensed for individuals with LFS. Preclinical studies in LFS murine models show that the anti-diabetic drug metformin is chemopreventive and, in a pilot intervention trial, short-term use of metformin was well-tolerated in adults with LFS. However, metformin's mechanism of anticancer activity in this context is unclear. METHODS: Metformin in adults with Li-Fraumeni syndrome (MILI) is a Precision-Prevention phase II open-labelled unblinded randomised clinical trial in which 224 adults aged ≥ 16 years with LFS are randomised 1:1 to oral metformin (up to 2 mg daily) plus annual MRI surveillance or annual MRI surveillance alone for up to 5 years. The primary endpoint is to compare cumulative cancer-free survival up to 5 years (60 months) from randomisation between the intervention (metformin) and control (no metformin) arms. Secondary endpoints include a comparison of cumulative tumour-free survival at 5 years, overall survival at 5 years and clinical characteristics of emerging cancers between trial arms. Safety, toxicity and acceptability of metformin; impact of metformin on quality of life; and impact of baseline lifestyle risk factors on cancer incidence will be assessed. Exploratory end-points will evaluate the mechanism of action of metformin as a cancer preventative, identify biomarkers of response or carcinogenesis and assess WB-MRI performance as a diagnostic tool for detecting cancers in participants with LFS by assessing yield and diagnostic accuracy of WB-MRI. DISCUSSION: Alongside a parallel MILI study being conducted by collaborators at the National Cancer Institute (NCI), MILI is the first prevention trial to be conducted in this high-risk group. The MILI study provides a unique opportunity to evaluate the efficacy of metformin as a chemopreventive alongside exploring its mechanism of anticancer action and the biological process of mutated P53-driven tumourigenesis. TRIAL REGISTRATION: ISRCTN16699730. Registered on 28 November 2022. URL: https://www.isrctn.com/ EudraCT/CTIS number 2022-000165-41.
引用
- Dixon-Zegeye M, Shaw R, Collins L, et al. Cancer Precision-Prevention trial of Metformin in adults with Li Fraumeni syndrome (MILI) undergoing yearly MRI surveillance: a randomised controlled trial protocol. Trials. 2024. PMID: 38308321. doi:10.1186/s13063-024-07929-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。